In vivo administration of picibanil (OK-432) prior to tumor harvest leads to an enhancement of tumor-infiltrating lymphocyte (TIL) cytotoxicity.
TILs can be isolated and expanded in vitro in the presence of RIL-2. The resulting cells are highly cytotoxic in vitro and in vivo against a variety of tumor targets. Although most of the TILs bear T cell antigens on their cell surface, recent evidence suggests that natural killer (NK) cells may be part of the overall population of infiltrating cells. Based upon this evidence, we have evaluated the effects of Picibanil (OK-432), a well-known inducer of NK cell and T cell cytotoxicity, on TILs. OK-432 was administered intravenously at a dose of 100 micrograms, previously determined to be optimal for NK stimulation, to tumor-bearing animals. Two days later, control and experimental animals had their tumors harvested and processed in order to grow their TILs in vitro in complete medium containing RIL-2 at a final concentration of 1,000 U/ml. The following observations were made: 1) a greater than 300% increase in overall TIL number compared to controls on day 10 of culture returning to normal by day 30; 2) a marked increase in the percent of cells expressing cytotoxic and differentiation antigens in the experimental group compared to controls, such increase seen mostly from day 7 to day 10; 3) a marked increase in the cytotoxic activity of the experimental TILs against an NK-sensitive tumor target, the YAC-1 lymphoma, throughout the period of growth of the TILs (3-4 times controls) and to a lesser extent against an NK-resistant tumor target. These findings may have potential application, in immunotherapeutic trials against human tumors and may help to understand the reasons for the effectiveness of OK-432 in vivo against selected murine tumors.
Division of Surgical Oncology, University of Calgary, Alberta, Canada.
R
R
Lafreniere
K
K
Borkenhagen
L D
LD
Bryant
D000230:Adenocarcinoma / Q000628:therapy; D000818:Animals; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis; D001688:Biological Products / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D005260:Female; D005455:Fluorescent Antibody Technique; D008223:Lymphoma / Q000628:therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000276:immunology / Q000628:therapy*; D010844:Picibanil / Q000494:pharmacology*; D011292:Premedication; D012513:Sarcoma, Experimental / Q000628:therapy; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects* / Q000276:immunology; D015854:Up-Regulation / Q000187:drug effects
D000945:Antigens, Differentiation, T-Lymphocyte; D001688:Biological Products; D010844:Picibanil